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Review
intRoduCtion
Management of glioma based on the National Comprehensive 
Cancer Network guidelines,[1] which consist of maximum 
safe resection followed by concurrent chemotherapy and 
radiation therapy, is a worldwide accepted standard. Whether 
this standard is followed or not depends on the capacity of 
health-care delivery in different parts of the world. Besides, 
the expenditure by the government in health-care delivery, 
demographics of the country, and socioeconomic condition 
of the population based on per capita income also determine 
the quality of health-care delivery.
Apart from the standard treatment (surgery, radiation, and 
chemotherapy), there are many other factors that improve the 
management of glioma. These additional factors in the form 
of methods, technologies, and techniques may or may not be 
supported by robust scientific evidence. These may include 
but are not limited to the state-of-the-art technology, such 
as magnetic resonance imaging (MRI) with diffusion tensor 
imaging capabilities, neuronavigation, intraoperative MRI, 
quality operative microscopes, and quality operating room 
proficiencies. Technologies such as fluorescence microscopy 
for resection of brain tumor using 5-aminolevulinic acid are 
not used in all the operating rooms of developed countries.[2] 
Similarly, the intraoperative MRI facility is not present in all the 
major hospitals of North America, Europe, or other developed 
countries.[2] Standard radiosurgery is offered in most of the 
major cities in the developed world, but highly specialized 
radiotherapy with proton beam radiotherapy is present only in 
a very few centers across the world. Temozolomide, which is 
the first line of chemotherapy available in most of the glioma 
management centers, is available almost all over the world, 
but specialized chemotherapeutic agents are not so readily 
available in developing countries.[3] When considering clinical 
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trials with experimental drug therapy, immunotherapy, or gene 
therapy, a significant disparity exists globally. These protocols 
based on clinical trials are poorly present or nonexistent in 
developing countries.
Glioma surgery in Pakistan is a complex, multifaceted 
dilemma. The outcome of glioma management is complicated 
by delayed diagnosis, lack of care in hospitals, delayed 
waiting time, and out-of-pocket payments in Pakistan.[4] This 
review investigates the current strategies and modalities of the 
treatment of different types of gliomas in Pakistan along with 
the consistent challenges posed to the patients and providers. 
Given the high workload, lack of advanced imaging and 
equipment, lack of adequate oncological services, and lack of 
quality control, glioma surgery may not be performed at the 
finest level in all the institutions despite the presence of trained 
neurosurgeons. Herein, we present a comprehensive review of 
costs and unique predicaments specific to a developing country 
with regard to glioma treatment. A thorough comparison 
between private and public sectors providing glioma treatment 
is presented in this article. In future, success in glioma surgery 
can be achieved with refined research and training, equitable 
access to advanced surgical care, provision of health-care 
delivery systems, and enhanced financing.
database seaRCh stRategy
The articles included in this review were retrieved from 
several databases such as PubMed and Google Scholar. They 
were found over a large span, that is, 20 years, as information 
was scarce. Research has barely been attempted in Pakistani 
demographics for brain tumors. This is the first analysis of 
glioma pertaining to Pakistani population. In this manner, our 
study is unique in the South Asian region. The MeSH terms 
included glioma, brain tumors, Pakistan, treatment, surgery, 
management, chemotherapy, and radiotherapy.
epidemiology
Pakistan has an ever-increasing population rate, with the 
current estimate at 207.7 million.[5] Primary studies on glioma 
incidence have not been previously conducted in Pakistan. 
The overall incidence rate of central nervous system tumors 
is 6.7/100,000, of which 51% comprises gliomas.[6] Therefore, 
extrapolating the worldwide incidence to the Pakistani 
population means the current burden of glioma in Pakistan 
is 7097 cases.
Role of diagnostiCs
Diagnostics play a substantial role in glioma surgery. To 
optimize treatment, glioma patients need to be followed up 
closely with postoperative MRI.[7] Most centers across Pakistan 
have a fully operable 1.5 Tesla machine. A 3 Tesla machine is 
only available at Aga Khan University Hospital (AKUH) and 
Armed Forces Institute of Radiology and Imaging, Pakistan. 
Moreover, only AKUH has diffusion tensor imaging and 
functional MRI facilities. While neuronavigation is available 
at many other facilities, it is not fully utilized for maximum 
safe resection, as tractography is not performed at other centers.
The cost of an MRI varies widely among private (Rupee [Rs.] 
23,680; United States dollar [USD] 167) versus public 
facilities (Rs. 5000; USD 35). An additional Rs. 13,510 
(USD 95) is charged for contrast. The cost of functional MRI 
is an overwhelming Rs. 69,700 (USD 493).[8] While patients 
get initial imaging done readily, the cost immediately piles up 
with repetitive images needed throughout the course of the 
treatment regimen. Only a few centers have formally trained 
neuroradiologists in Pakistan.
suRgeRy
There are significant differences in quality care between 
private and public sectors, entailing both intra-operative and 
postoperative care. In public sector institutions, there is a high 
burden of patients due to much lower costs, and administrative 
issues result in further turbulence in the provision of quality 
patient care. Some public sector hospitals such as Lahore 
General Hospital and Dow University Hospital, Karachi, 
Pakistan, have functioned exceptionally well at performing 
the arduous task of maintaining minimal costs with a difficult 
combination of providing substantial treatment.
Certain differences generally exist between private and 
public sector institutions. While private sector institutions 
have more accountability, better quality and standards, and 
a multidisciplinary approach to patients, they remain beyond 
reach for the larger public. Public sectors, on the other hand, 
remain less costly, but there is a serious lack of enough beds, 
lengthy waiting time, and minimal checks and balances. 
Table 1 compares the finances between private and public 
sector hospitals.
The waiting time is an important parameter to consider in 
glioma surgery.[9] In private sector institutions, such as in 
AKUH, the average waiting time for surgical resection for 
high-grade glioma is <2 weeks, unless emergent care is 
required for significant mass effect or impending herniation. 
For low-grade glioma, the waiting time for surgical resection 
is longer. For public sector hospitals, although clinics generally 
walk in without waiting time, it may take more than 6 weeks 
for surgical resection.[10]
Awake craniotomy is a standard method for glioma surgery, 
particularly focusing on eloquent areas, which has been 
established only in one center (AKUH) in Pakistan. While 
Table 1: Comparison of costs among private and public 
institutions in USD
Private Public
Surgical resection 4025.82 353.36
Intensive care unit stay 618.38 141.34
3-Dimensional radiotherapy per session 72.79 7.07
Dollar rate: 1.00 USD equals 141.50 Pakistani rupee. USD: United States 
dollar
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differentiating normal brain tissue from the tumor.[12,13] Because 
5-aminolevulinic acid is costly (approximately USD 1200) 
and can increase the cost of surgery by as much as 25%, 
fluorescein is used as an inexpensive alternative. The problem 
with fluorescein is that it can appear in normal tissue with a 
high nonspecificity of fluorescence.[14]
The selection of innovative and instrumental technologies 
while weighing the cost-effectiveness is a constant struggle for 
neurosurgeons in Pakistan. It results in significant limitations 
for surgeons in providing the best outcome for their patients. 
Table 2 compares the cost of craniotomy along with innovative 
technologies.
histopathology
Several tertiary care centers across the country have an 
adjoining histopathology laboratory. If a histopathology 
laboratory is not associated with the center, the specimen 
is sent elsewhere in the city for analysis. A few laboratory 
centers including AKUH and SKMH have the state-of-the-art 
technology with the latest molecular tests, such as isocitrate 
dehydrogenase, O-6-methylguanine-DNA methyltransferase, 
and 1p19q co-deletion. Frozen section is available at most 
major centers such as AKUH, SKMH, and Dow University 
Hospital.[15] Due to volume overload, it may take 2 weeks for 
a final histopathological report.
tumoR boaRds
Tumor boards serve as multidisciplinary conduits of 
communication, teaching, coordination among specialists, 
and future research directions.[16] There are nonspecialized 
tumor boards available across the country, but, unfortunately, 
very few centers in Pakistan are currently conducting 
specialized tumor boards dedicated to brain tumors, with a few 
exceptions such as AKUH, SKH, and Lahore General Hospital. 
Nevertheless, informal discussions on difficult cases may exist 
at all cancer centers, as teamwork and a holistic approach are 
vital for patient outcomes.
RadiotheRapy
Because Pakistan is a developing country, only a few key 
centers play a major role in providing radiotherapy. The rest 
several hurdles may exist owing to the limitation of resources, 
lack of neuro-anesthesia training, and low overall literacy in 
Pakistan, the outcomes remain promising owing to patient’s 
and surgeon’s satisfaction.[7,11]
Follow‑up of patients
Another prevalent reason for poor outcomes is the issue of loss 
of follow-up. Despite the detailed peri-operative discussion, 
a prevalent notion among uneducated patients is that surgical 
resection is the terminal cure for brain tumors. Consequently, 
patients often fail to visit the oncology department after 
discharge from the hospital.[10] In such circumstances, the 
postoperative MRI may not get performed at regular intervals, 
and it becomes difficult to identify recurrence in time. The 
topmost reasons for loss to follow-up according to our 
institutional review include communication gap, financial 
burden, inconvenience, and inaccessibility from far-flung 
areas.
Postoperative care
The average length of stay in AKUH is 5 days.[10] The average 
length of stay varies between public and private sectors. In 
public sectors, patients sometimes must be admitted several 
days in advance to get on the list for surgery. Similarly, the 
discharge stay may be more than needed, but that is highly 
variable across the country. Postoperative nursing care is still 
not up to international standards at many other private centers, 
as only three private hospitals (AKUH, Shaukat Khanum 
Memorial Hospital [SKMH], and Shifa International Hospital) 
and none of the public sector hospitals are Joint Commission 
International Accredited. Surgical morbidity increases with an 
inadequate level of postoperative care in public and private 
sectors.
Availability of high‑end technology
Most centers currently have the availability of operative 
neurosurgical microscopes. Neuronavigation and ultrasonic 
aspirator are available in less than a tenth of all the centers 
that perform glioma resection, while operative exoscope is 
available only at AKUH. The problem with most of these 
equipment is that the added costs of disposables required for 
their use act as a deterrent.[10]
Fluorescent microscopy facility is available only at AKUH 
along with 5-aminolevulinic acid which is a technique in 
Table 2: Cost comparison of craniotomy to added technological advancements
Technology Cost in rupees Cost in USD Proportion (%)
Craniotomy 569,654 4025 60
Ultrasonic aspirator 60,000 424 7
Functional magnetic resonance imaging 83,210 588 9
Neuronavigation 60,000 424 6
Exoscope 20,000 141 2
Fluorescent microscopy with 5-aminolevulinic acid 169,800 1200 15
Fluorescent microscopy with fluorescein 12,000 84 1
Total 946,364 6688 100
Dollar rate: 1.00 USD equals 141.50 Pakistani rupee. USD: United States dollar
[Downloaded free from http://www.jglioma.com on Friday, January 31, 2020, IP: 10.232.74.27]
Abdullah, et al.: Glioma management in Pakistan
Glioma ¦ Volume 2 ¦ Issue 3 ¦ July-September 2019142
21 centers are solely dedicated to cancer care.[4] Furthermore, 
in developing countries, temozolomide is primarily imported 
from other countries and with the growing economic 
constraints, cost of chemotherapeutic drugs rapidly rises.[2]
Availability of drugs is uncertain in some centers across 
Pakistan although it is mostly available at others, including 
AKUH. Cost of temozolomide adds to the patient’s expenses 
as the monthly expense come close to Rs. 150,000 (USD 1060). 
Depending on the manufacturing country of the drug, the cost 
declines (Rs. 31,000; USD 219). The availability and utilization 
of bevacizumab (Avastin) vary at different centers, as the cost 
is hefty for the patient population at Rs. 102,192 (USD 722) 
for 400 mg of bevacizumab.[15]
finanCes
The burden of glioma patients in Pakistan is further 
complicated by reduced spending on health. The gross national 
income per capita for Pakistanis is USD 5840, which, although 
on a rising trend, is drastically lower compared to that of other 
countries.[9] According to World Health Organization statistics 
of 2014, the total expenditure on health per capita is USD 129, 
whereas the total expenditure on health as a percentage of 
gross domestic product is 2.6%.[19] Altogether, the total health 
expenditure as of 2015–2016 was Rs. 907,504 million (USD 
6413 million) as drafted by the National Health Accounts. 
Government spending from various sources is a mere 32% of 
the total health expenditure, whereas out-of-pocket payments 
form an immense 58%, as of 2015 government data.[20] There 
is an urgent need to address health-care spending specifically 
toward cancer. Table 3 depicts health-care expenditure from 
all sources from 2015 to 2016.
As Pakistan is a low middle-income country, surgical access 
remains a hindrance to adequate care. Currently, 24.3% 
of Pakistan’s population lives below the poverty line.[21] 
Considering all these statistics, in addition to the fact that most 
of the population live in rural areas, surgical access for glioma 
surgery remains cumbersome for patients. A study conducted 
by Samad et al.[22] portrayed barriers behind accessing surgical 
care. Gender is the topmost reason as women are twice more 
likely to delay access compared to men. Various other reasons 
include insufficient knowledge of treatment options and disease 
of the centers have an unmet need for facilities, technological 
staff, nurses, and trained personnel. Eighteen centers belong to 
Pakistan Atomic Energy Commission, a government body.[17] 
Nine other private centers are functioning throughout the 
four provinces. Unfortunately, some centers do not follow 
internationally accepted treatment guidelines, despite the 
availability of high-quality radiotherapy machines. Two centers 
in Pakistan are offering stereotactic radiosurgery (gamma knife 
and cyberknife in Karachi), and only four centers in Pakistan 
are offering intensity-modulated radiation therapy.
Considering logistic issues, every center has its own treatment 
guideline regarding low-grade glioma, keeping the prompt 
provision of radiotherapy following surgical resection in 
consideration. At AKUH, radiotherapy for all gliomas is 
typically commenced 4–6 weeks after surgical resection. 
For high-grade gliomas, the radiation oncologists aim to 
start treatment within 4 weeks of surgical resection, and as 
soon as the wound is healed. While public sector hospitals 
are appealing due to cost, gaps within treatment routinely 
occur due to out-of-order machines. The patients hence 
wait for months for the resumption of treatment. It may take 
4–6 months for radiotherapy to start at public sector hospitals 
after surgical resection. Because not all centers have a 
coexisting radiotherapy department, the patients must search 
for radiotherapy elsewhere, thereby not fulfilling the treatment 
guidelines. At AKUH, three-dimensional (3D) radiotherapy 
costs Rs. 10,300 (USD 73), whereas intensity-modulated 
radiation therapy costs Rs. 17,000 (USD 120) per session. 
The total cost of radiotherapy alone climbs up to Rs. 400,000 
(USD 2827) to Rs. 600,000 (USD 4240) depending on the case 
in most private sectors. SKMH is an exception as a private 
center that offers radiotherapy free of charge. At some public 
centers, such as Karachi Institute of Radiotherapy and Nuclear 
Medicine, the cost is minimal at Rs. 1000 (USD 7) per session 
for 3D technology. The total average cost of radiotherapy for 
a public sector hospital is hence Rs. 30,000 (USD 212).[18]
ChemotheRapy
More than fifty hospitals have the capacity to deliver 
chemotherapy across Pakistan. Yet, very few hospitals have an 
adequate health-care system with trained personnel. Another 
Table 3: Total health expenditures (2015–2016) by financing agents in millions of rupees and United States dollar millions[20]
Financing agents Millions of rupees USD equivalent millions (USD) Proportion (%)
Federal government 67,062 473.94 7.38
Provincial government 187,096 1322.23 20.62
District/tehsil government 39,405 278.48 4.34
Social security funds 9538 67.41 1.05
Autonomous bodies/corporations 14,287 100.97 1.57
Private household out-of-pocket payment 522,571 3693.08 57.58
Local nongovernmental organizations 44,271 312.87 4.87
Official donor agencies 15,210 107.49 1.68
Total health expenditure 907,504 6413.46 100
Dollar rate: 1.00 USD equals 141.50 Pakistani Rupee. USD: United States dollar
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implications, financial constraints, and environmental-related 
aspects (such as geographical location and city disturbances).[22]
Finances between private and public sectors also differ. 
While private hospitals such as SKMH, Shifa International 
Hospital, and AKUH have a functional health-care system 
with adequate administration, hefty hospital charges may turn 
many patients away. Nevertheless, a lot of these expensive 
centers notably provide welfare to deserving patients. Figure 1 
provides comparisons of all the current treatment modalities 
for glioma surgery.
CapaCity building
According to estimates, Pakistan’s population-to-surgeon 
ratio is one of the worst in the world (second only to a 
few sub-Saharan African countries), and there is a deficit 
of 17 million surgeries every year.[23] Data published in 
2011 revealed an estimated 42 dedicated neurosurgery 
centers across the country, with only about 1500 dedicated 
neurosurgery beds, a number extremely low for Pakistan’s 
population.[24] While all these centers can deal with 
neurotrauma, spine, and even basic neurosurgical oncology, 
due to limited resources, only a few centers in Pakistan are 
fully exercising their potential to treat gliomas. According 
to the regulatory body for neurosurgery residency, College 
of Physicians and Surgeons, Pakistan, at present, there are 
330 practicing neurosurgeons.[25]
While the worldwide ratio is one neurosurgeon per 230,000 
people (and approximately one neurosurgeon for 61,000 
persons in the USA),[26] the ratio in Pakistan is one neurosurgeon 
per 629,620 people. Hence, the ratio of US neurosurgeons is 
10.3 times more, and worldwide, neurosurgeons are 2.7 times 
more compared to Pakistan.[24]
Quality of tRaining in paKistan
As it currently stands, few neurosurgical residency 
programs are providing exceptional training, whereas 
most are struggling to maintain quality. Comprehensive 
teaching – including basic neuroscience lectures, hands-on 
surgical workshops, and research – is a significant 
cornerstone of any neurosurgical residency. Very few 
fellowship-trained oncological neurosurgeons are available, 
with AKUH being the only center that has recently started 
providing an academic fellowship in neurosurgical oncology. 
Moreover, there is no organized society dedicated to 
neurosurgical oncology. Presently, there are 177 trainees in 
31 teaching institutes across the country, with approximately 
50 supervisors.[25]
Quality of ReseaRCh in paKistan
Another arena not well developed across Pakistan is basic 
science research focusing on neuro-oncology. Our laboratory 
is focusing on the diagnostic and therapeutic potential of 
microRNA in glioma, and glioma-initiating cells. Most centers 
perform either very little research or mainly retrospective 
studies, with little progress over the last half decade.[27] Centers 
have not focused on randomized controlled trials or clinical 
Figure 1: Comparison of costs of the modalities of treatment in United 
States dollar (USD) in a private hospital. Dollar rate: 1.00 USD equals 
141.50 Pakistani rupee. Chemotherapy costs of temozolomide averaged 
for six cycles. Radiotherapy (three dimensional) averaged for thir ty 
fractions
Figure 2: Quality of research and training in neurosurgical residency 
programs in Pakistan[24]
Figure 3: Academic shortcomings of neurosurgical trainees in Pakistan.[24] 
M&M: Morbidity and mortality meeting
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trials either. Figures 2 and 3 represent the quality of research 
and training in Pakistan, along with the academic shortcomings 
of neurosurgical trainees.
From all the literatures published within Pakistan in the last 
10 years, a large proportion is composed of case studies and 
case series. These are often seen from large tertiary care centers 
within the region, whereas primary and secondary health-care 
centers have a very low representation in literature. This is 
often due to a lack of neurosurgical expertise within these 
centers. Most clinical research is published. AKUH remains 
the largest research publishing center within the country, with 
a high number of prospective and retrospective, cohort and 
cross-sectional studies.[3]
From a city comparison, hospitals in Lahore such as SKMH and 
the Lahore General Hospital have a rapidly growing number of 
publications, followed closely by Karachi. This is reflective of 
Lahore having a much larger catchment area. However, most 
of these studies are published in non-PubMed indexed, and 
local journals, which allows for a wide deviation of quality of 
paper, and greatly limits the readership of the paper.
ConClusion
Issues surrounding glioma surgery in Pakistan can only 
be tackled with a holistic approach toward multiple and 
multilayered constraints. There is an urgent need to deal 
with various obstacles to achieve seamless outcomes for 
glioma surgery. Improved health-care delivery systems to 
provide systematic care and to achieve greater follow-ups, 
enhanced funding to achieve newer advancements in care, and 
improvement of education and research at an increasing number 
of centers are all required on an immediate basis. Without these 
quick and dire approaches, outcomes may remain dismal for 
years. Problem-solving of a specific neurosurgical issue such as 
glioma surgery can only be attempted when other various facets 
of health care are addressed simultaneously. One also needs 
to reflect on the cost paid by the family to treat glioblastoma 
comprehensibly, when the overall life expectancy of the disease 
is increased on an average by only 9 months.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
RefeRenCes
1. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, 
et al. NCCN guidelines insights: Central nervous system cancers, 
version 1.2017. J Natl Compr Canc Netw 2017;15:1331-45.
2. Salem A, Hashem SA, Al-Rashdan A, Ezam N, Nour A, Alsharbaji A, 
et al. The challenges of managing glioblastoma multiforme in 
developing countries: A trade-off between cost and quality of care. 
Hematol Oncol Stem Cell Ther 2011;4:116-20.
3. Shamim MS, Enam SA, Kazim SF. Neurosurgical research in Pakistan: 
Trends of publication and quality of evidence. Clin Neurol Neurosurg 
2011;113:107-10.
4. Yusuf A. Cancer care in Pakistan. Jpn J Clin Oncol 2013;43:771-5.
5. Hausmann A, Weis C, Marksteiner J, Hinterhuber H, Humpel C. 
Chronic repetitive transcranial magnetic stimulation enhances c-fos 
in the parietal cortex and hippocampus. Brain Res Mol Brain Res 
2000;76:355-62.
6. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the 
United States, 1977-2000. Cancer 2004;101:2293-9.
7. Shafiq F, Parkash J, Enam A, Khan MF, Baig T. An awake throughout 
approach for awake craniotomy: A perspective from a resource-limited 
country. World Neurosurg 2019. pii: S1878-8750 (19) 30805-8.
8. Glover L. Why Does an MRI Cost So Darn Much? Available from: 
http://money.com/money/2995166/why-does-mri-cost-so-much. [Last 
accessed on 2019 Jan 12].
9. Hallett M. Transcranial magnetic stimulation: A primer. Neuron 
2007;55:187-99.
10. Finance Department, The Aga Khan University Hospital, Karachi. 
Available from: https://www.aku.edu. [Last verified on 2019 Jan 10].
11. Khan SA, Nathani KR, Enam SA, Shafiq F. Awake craniotomy in 
developing countries: Review of hurdles. IJS Short Rep 2017;2:5-9.
12. Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit 
of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of 
malignant gliomas? Neurosurgery 2015;77:663-73.
13. Waqas M, Khan I, Shamim MS. Role of 5-ALA in improving extent of 
tumour resection in patients with glioblastoma multiforme. J Pak Med 
Assoc 2017;67:1630-2.
14. Stummer W, Suero Molina E. Fluorescence imaging/Agents in tumor 
resection. Neurosurg Clin N Am 2017;28:569-83.
15. Pharmacy Department, The Aga Khan University Hospital, Karachi. 
Available from: https://www.aku.edu. [Last verified on 2019 Jan 10].
16. Snyder J, Schultz L, Walbert T. The role of tumor board conferences 
in neuro-oncology: A nationwide provider survey. J Neurooncol 
2017;133:1-7.
17. Liu H, Shubayev VI. Matrix metalloproteinase-9 controls proliferation 
of NG2+progenitor cells immediately after spinal cord injury. Exp 
Neurol 2011;231:236-46.
18. Billing Department, Dr. Ruth Pfau Hospital, Karachi. Available from: 
https://chk.gov.pk. [Last verified on 2019 Jan 10].
19. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 
London: Academic Press; 2005.
20. Pakistan Bureau of Statistics, Statistics Division, Government of 
Pakistan. National Health Accounts Pakistan 2015-16. Available 
from: http://www.pbs.gov.pk/sites/default/files//NHA-Pakistan%20
2015-16%20Report_0.pdf. [Last accessed on 2019 Jan 13].
21. Hölscher C. Drugs developed for treatment of diabetes show protective 
effects in Alzheimer’s and Parkinson’s diseases. Sheng Li Xue Bao 
2014;66:497-510.
22. Samad L, Jawed F, Sajun SZ, Arshad MH, Baig-Ansari N. Barriers 
to accessing surgical care: A cross-sectional survey conducted 
at a tertiary care hospital in Karachi, Pakistan. World J Surg 
2013;37:2313-21.
23. Zafar SN, McQueen KA. Surgery, public health, and Pakistan. World J 
Surg 2011;35:2625-34.
24. Shamim MS, Tahir MZ, Godil SS, Kumar R, Siddiqui AA. A critical 
analysis of the current state of neurosurgery training in Pakistan. Surg 
Neurol Int 2011;2:183.
25. College of Physicians and Surgeons Pakistan. Available from: https://
www.cpsp.edu.pk/. [Last accessed on 2019 Jan 13].
26. Kenning TJ. Neurosurgical Workforce Shortage: The Effect of 
Subspecialization and a Case for Shortening Residency Training. 
Available from: https://aansneurosurgeon.org/departments/
neurosurgical-workforce-shortage-effect-subspecialization-cast-
shortening-residency-training/. [Last accessed on 2019 Jan 13].
27. Waqas M, Siddiqui UT, Shamim MS. Follow-up bibliometric analysis of 
neurosurgical publications from Pakistan and institutional comparison 
with other countries using h-index and i-10 index. Asian J Neurosurg 
2019;14:126-30.
[Downloaded free from http://www.jglioma.com on Friday, January 31, 2020, IP: 10.232.74.27]
